Holen Sie sich die Stockscreener-App
0.811
4.40%
-0.0373
Schlusskurs vom Vortag:
$0.8483
Offen:
$0.83
24-Stunden-Volumen:
74,043
Relative Volume:
0.17
Marktkapitalisierung:
$9.45M
Einnahmen:
$37.17M
Nettoeinkommen (Verlust:
$-17.57M
KGV:
-0.4463
EPS:
-1.8172
Netto-Cashflow:
$-12.01M
1W Leistung:
-8.84%
1M Leistung:
-4.54%
6M Leistung:
-15.51%
1J Leistung:
-10.01%
1-Tages-Spanne:
$0.8005
$0.8375
1-Wochen-Bereich:
$0.78
$0.9601
52-Wochen-Spanne:
$0.536
$1.19
Biofrontera Inc Stock (BFRI) Company Profile
Firmenname
Biofrontera Inc
Sektor
Telefon
781-245-1325
Adresse
120 PRESIDENTIAL WAY,, WOBURN
Compare BFRI vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BFRI
Biofrontera Inc
|
0.811 | 9.45M | 37.17M | -17.57M | -12.01M | -1.8172 |
TAK
Takeda Pharmaceutical Co Adr
|
18.04 | 56.99B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
115.93 | 48.94B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.30B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.14 | 33.94B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
531.82 | 23.31B | 3.18B | 1.33B | 1.04B | 27.90 |
Biofrontera Inc Aktie (BFRI) Neueste Nachrichten
Biofrontera reports rise in Q4 revenue, turns profitable - MSN
If You Invested $1,000 in Biofrontera Inc (BFRI) - Stock Titan
Layoff Watch: Is Biofrontera Inc forming a breakout pattern2026 PostEarnings & High Conviction Buy Zone Alerts - baoquankhu1.vn
Biofrontera Inc (BFRI) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
BFRI PE Ratio & Valuation, Is BFRI Overvalued - Intellectia AI
Biofrontera’s New Royalty Agreement Drives Gross Margins Above 82%, Opening Up New Profit Opportunities - Bitget
Biofrontera Inc. (NASDAQ:BFRI) Q4 2025 Earnings Call Transcript - Insider Monkey
Biofrontera Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Biofrontera 2025 Company Overview: Ameluz Photodynamic Therapy, Product Pipeline, and U.S. Market Strategy - Minichart
Biofrontera Earnings Call: Profits Rise, Risks Remain - TipRanks
BFRIW SEC FilingsBiofrontera 10-K, 10-Q, 8-K Forms - Stock Titan
BIOFRONTERA ($BFRI) Releases Q4 2025 Earnings - Quiver Quantitative
[10-K] Biofrontera Inc. Files Annual Report | BFRI SEC FilingForm 10-K - Stock Titan
Biofrontera outlines 80%-85% gross margin target for 2026 following strategic asset acquisition - MSN
Biofrontera Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2025 - marketscreener.com
Earnings call transcript: Biofrontera Inc. Q4 2025 sees record revenue growth - Investing.com Australia
Biofrontera 2025 Financial Results: Record Annual & Quarterly RevenueNews and Statistics - IndexBox
Biofrontera Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Biofrontera (BFRI) Q4 2025 Financial Results Transcript - Bitget
Biofrontera (BFRI) Q4 2025 Earnings Transcript - The Globe and Mail
BFRI: Record revenue, improved margins, and clinical progress set up strong 2026 growth - TradingView
Biofrontera reports Q4 revenue $17.1M vs. $12.6M last year - TipRanks
Biofrontera reports record Q4 revenue $17.1M, Q4 gross margin 82.4% and Q4 net income $5.6M - TradingView
Record Q4 for Biofrontera (NASDAQ: BFRI) with 36% revenue growth - Stock Titan
Biofrontera turns Q4 profitable after cutting Ameluz earnout payments - Stock Titan
Price Action: Does Biofrontera Inc have a sustainable dividend2026 Pullbacks & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Nasdaq Moves: Does Biofrontera Inc Equity Warrant have pricing power2026 Snapshot & Real-Time Chart Breakout Alerts - baoquankhu1.vn
Biofrontera Inc expected to post earnings of 20 cents a shareEarnings Preview - TradingView
BFRIWBiofrontera Latest Stock News & Market Updates - Stock Titan
Analysts Offer Insights on Healthcare Companies: OS Therapies Incorporated (OSTX), Legend Biotech (LEGN) and Biofrontera (BFRI) - The Globe and Mail
Biofrontera (BFRI) to Release Earnings on Thursday - Defense World
Are healthcare shares trailing behind Align Technology (ALGN) in performance this year? - Bitget
PTA-Adhoc: Biofrontera AG: Financial Guidance for FY 2026 - TradingView
Market Rankings: Is Biofrontera Inc backed by strong institutional buying2026 Opening Moves & Verified Swing Trading Watchlists - baoquankhu1.vn
Biofrontera Inc. (BFRI) Upgraded to Buy: Here's Why - Bitget
Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026 - The Manila Times
Biofrontera Inc. to Report Fourth Quarter and Full Year - GlobeNewswire
Biofrontera Inc. (BFRI) upgraded to buy: Here's why - MSN
Biofrontera reports Phase 2b acne trial results for Ameluz PDT - Investing.com India
Biofrontera Reports Positive Phase 2b Acne Trial Results - TipRanks
Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris - The Manila Times
Biofrontera reports positive Phase 2b Ameluz PDT results for moderate to severe acne - TradingView
Biofrontera Inc. Reports Positive Phase 2b Results - GlobeNewswire
Is Biofrontera Inc. backed by strong institutional buyingQuarterly Portfolio Summary & Safe Entry Trade Reports - baoquankhu1.vn
Loss Report: Does Biofrontera Inc have a sustainable dividendDollar Strength & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Biofrontera (BFRI) director awarded 20,000-share employee stock option grant - Stock Titan
Biofrontera grants RSUs and options to... | BFRI Insider Trading - Stock Titan
BFRIW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Will Biofrontera Inc. stock go up in YEAR2025 Top Gainers & Risk Controlled Stock Alerts - mfd.ru
Biofrontera wins patent ruling against Sun Pharma in dispute By Investing.com - Investing.com Australia
Bank Watch: Is Biofrontera Inc a play on infrastructure spendingJuly 2025 Final Week & AI Enhanced Execution Alerts - baoquankhu1.vn
Finanzdaten der Biofrontera Inc-Aktie (BFRI)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.75%
1.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):